These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 21855758

  • 1. Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery.
    Miyake K, Ota I, Miyake G, Numaga J.
    J Cataract Refract Surg; 2011 Sep; 37(9):1581-8. PubMed ID: 21855758
    [Abstract] [Full Text] [Related]

  • 2. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%.
    Asano S, Miyake K, Ota I, Sugita G, Kimura W, Sakka Y, Yabe N.
    J Cataract Refract Surg; 2008 Jan; 34(1):57-63. PubMed ID: 18165082
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation.
    Miyake K, Nishimura K, Harino S, Ota I, Asano S, Kondo N, Miyake S.
    Invest Ophthalmol Vis Sci; 2007 Dec; 48(12):5647-52. PubMed ID: 18055815
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification.
    Sahu S, Ram J, Bansal R, Pandav SS, Gupta A.
    J Cataract Refract Surg; 2015 Oct; 41(10):2043-8. PubMed ID: 26703278
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial.
    Duong HV, Westfield KC, Chalkley TH.
    J Cataract Refract Surg; 2007 Nov; 33(11):1925-9. PubMed ID: 17964399
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intraindividual comparison of nepafenac 0.3% for the prevention of macular edema after phacoemulsification.
    Tzelikis PF, Morato CS, Neves NT, Hida WT, Alves MR.
    J Cataract Refract Surg; 2018 Apr; 44(4):440-446. PubMed ID: 29685777
    [Abstract] [Full Text] [Related]

  • 15. Prevention of post cataract-surgery cystoid macular edema with nepafenac.
    Glasser DB.
    J Cataract Refract Surg; 2012 Jan; 38(1):187; author reply 188. PubMed ID: 22153112
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery.
    Lane SS, Modi SS, Lehmann RP, Holland EJ.
    J Cataract Refract Surg; 2007 Jan; 33(1):53-8. PubMed ID: 17189793
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.